{
}
UBS has maintained a "Buy" rating for Merck KGaA, setting a target price of 180 euros. Analyst Matthew Weston anticipates mixed first-quarter results, with a solid performance in the Healthcare division and signs of recovery in Life Science Bioprocessing, though demand for Life Science Lab Solutions remains weak and the outlook for Semiconductors is uncertain.
UBS has assigned AstraZeneca a "Buy" rating with a target price of 14,200 pence following the company's quarterly results. Analyst Matthew Weston noted a mixed performance but confirmed the company's outlook in his initial assessment.
UBS has assigned Astrazeneca a "Buy" rating with a target price of 14,200 pence following the company's mixed quarterly performance, which included a confirmation of its outlook. Analyst Matthew Weston provided this assessment in his initial reaction.
UBS AG has maintained a "Buy" rating for Merck KGaA, setting a target price of 180 euros, following the company's planned acquisition of Springworks, which aligns with its strategic goals. Merck shares rose 0.7% to EUR 120.60, indicating a 49.25% upside potential, despite a 13.8% decline since the start of 2025.
UBS AG maintains a "Buy" rating for Roche shares with a target price of 338 francs, following a strong first quarter where sales exceeded estimates by 2%. The share price rose 0.2% to CHF 258.70, indicating a potential upside of 30.65%. Roche's production capacity expansion in the USA is viewed positively amid import tariff concerns.
UBS has maintained a "Buy" rating for Roche, setting a target price of 338 francs following the company's first-quarter results, which surpassed sales expectations by 2%. Analyst Matthew Weston highlighted the positive impact of Roche's increased production capacities in the U.S. amid import tariffs.
UBS AG has maintained a "Neutral" rating for Sartorius vz shares, setting a target price of 302 euros, following positive first-quarter figures, particularly in the bioprocess technology segment. The share price rose 3.3% to EUR 200.60, indicating a potential upside of 50.55% relative to the target. However, the stock has seen a decline of 6.5% since the start of 2025, with Q1 2025 financial results expected on April 16, 2025.
Deutsche Bank has raised its price target for Novartis shares to CHF115 from CHF110, maintaining a Buy rating, driven by optimism surrounding the cancer treatment Pluvicto's label expansion. The company shows strong financial health with a 10.85% revenue growth and a gross profit margin of 75.22%. In contrast, UBS downgraded Novartis from Buy to Neutral, lowering the target to CHF104, citing concerns over upcoming patent expirations that may hinder growth.
UBS has maintained its "Buy" rating for Astrazeneca, setting a target price of 14,200 pence. Analyst Matthew Weston highlighted promising study results for the cholesterol-lowering drug AZD0780 presented at the US Cardiologists Congress.
UBS has maintained a "Buy" rating for AstraZeneca with a target price of 14,200 pence. Analyst Matthew Weston advised caution regarding the Calypso study results for Enebo, a treatment for hypothyroidism, noting the absence of a "clinically significant" designation for the primary endpoint and lack of independent expert commentary, suggesting unmet competitive expectations.
Matthew Weston
People
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
ubs maintains buy rating for merck with target price of 180 euros
11:17 08.05.2025
ubs rates astrazeneca as buy with target price of 14200 pence
22:38 29.04.2025
ubs rates astrazeneca as buy with target price of 14200 pence
14:51 29.04.2025
ubs maintains buy rating for merck shares with target price of 180 euros
12:19 25.04.2025
ubs maintains buy rating for roche with positive sales outlook
14:58 24.04.2025
ubs maintains buy rating for roche with target price of 338 francs
13:40 24.04.2025
ubs maintains neutral rating for sartorius with target price of 302 euros
13:58 19.04.2025
Deutsche Bank raises Novartis price target amid Pluvicto optimism
13:47 03.04.2025
ubs maintains buy rating for astrazeneca with target price of 14200 pence
10:50 01.04.2025
ubs maintains buy rating for astrazeneca amid cautious study results
12:47 17.03.2025
Trending
Subcategory
Corporate News
Industry Trends
Venture Capital Investments
Cryptocurrency Trends
Emerging Startups
Funding Rounds & Investments
AI Innovations
Retail and Consumer Goods
Crypto Adoption and Integration
Fintech Startups
Startups & Entrepreneurship
AI Applications
Economic Indicators
Crypto Policies and Governance
Product Launches
Workplace Trends
Central Banks and Digital Currencies
IPOs of Tech Companies
Market Analysis and Predictions
IPOs & SPACs
Countries:
Companies:
Apple Inc.
Nvidia Corporation
DEUTSCHE BANK AG
EVOLUTION JAPAN Securities Co. Ltd.
Alphabet Inc.
Marvell Technology Inc.
Playtika Holding Corp.
Colugo Systems Ltd.
Gemini Trust Company LLC
Circle Internet Financial Inc.
Citigroup Inc.
Bank of America Corporation
Sony Corporation
Zero Networks Ltd.
Ecom Express Ltd.
Minebea Mitsumi Inc.
VOLKSWAGEN AG
Currencies:
People: